Hu Diangeng, Zhao Jianxin, Zhang Hao, Wang Gang, Gu Zhennan
State Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi 214122, China.
School of Food Science and Technology, Jiangnan University, Wuxi 214122, China.
Life (Basel). 2023 Jun 30;13(7):1488. doi: 10.3390/life13071488.
An analysis of the weight and blood glucose management associated with fecal microbiota transplantation (FMT) as well as metabolic diseases associated with FMT was conducted by the authors in order to provide clinical recommendations regarding the treatment of nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). We searched PubMed, Embase, and the Cochrane Library for papers that were published between the creation of the database and October 2022. We reviewed research that investigated how FMT affected weight and glycemic management in cases of obesity and metabolic conditions that are related to obesity. Studies that were published more than once, lacked the entire text, included insufficient information, or were impossible to extract data from were excluded. Additionally, case reports, reviews, and systematic reviews were excluded from the analysis. In order to analyze the data, STATA 15.1 was used. When we combined all of our findings, we discovered that pooled outcomes showed that weight levels (WMD equals -4.77, 95%CI: -7.40-2.14), BMI levels (WMD equals -1.59, 95%CI: -2.21-0.97), HOMA-IR (WMD equals -0.79, 95%CI: -1.57-0.00), and HbA1c (WMD equals -0.65, 95%CI: -0.75-0.55) after FMT treatment were significantly lower than before treatment. However, FMT treatment may have no effect on glucose and insulin levels in obese patients at fasting and related metabolic diseases. Additionally, subgroup analysis outcomes found that FMT significantly reduced fasting blood glucose in people with diabetes. As a weight loss and glycemic control therapy, FMT helps to prevent and treat metabolic problems linked to obesity, and is a viable alternative to bariatric surgery for patients who do not wish to undergo the procedure.
作者对粪便微生物群移植（FMT）相关的体重和血糖管理以及与FMT相关的代谢性疾病进行了分析，以便为非酒精性脂肪性肝病（NAFLD）和2型糖尿病（T2DM）的治疗提供临床建议。我们在PubMed、Embase和Cochrane图书馆中搜索了从数据库创建到2022年10月期间发表的论文。我们回顾了研究FMT如何影响肥胖及与肥胖相关的代谢状况患者的体重和血糖管理的研究。重复发表、缺乏全文、信息不足或无法从中提取数据的研究均被排除。此外，病例报告、综述和系统评价也被排除在分析之外。为了分析数据，使用了STATA 15.1。当我们综合所有研究结果时，发现汇总结果显示，FMT治疗后的体重水平（加权均数差等于-4.77，95%置信区间：-7.40-2.14）、体重指数（BMI）水平（加权均数差等于-1.59，95%置信区间：-2.21-0.97）、胰岛素抵抗指数（HOMA-IR）（加权均数差等于-0.79，95%置信区间：-1.57-0.00）和糖化血红蛋白（HbA1c）（加权均数差等于-0.65，95%置信区间：-0.75-0.55）均显著低于治疗前。然而，FMT治疗可能对肥胖患者的空腹血糖和胰岛素水平及相关代谢性疾病没有影响。此外，亚组分析结果发现，FMT可显著降低糖尿病患者的空腹血糖。作为一种减肥和血糖控制疗法，FMT有助于预防和治疗与肥胖相关的代谢问题，对于不希望接受减肥手术的患者来说，是一种可行的替代方案。
